References
- Belchetz P E. Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330: 1062–71
- Lindsay R, Hart D M, Clark D M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759–63
- Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736–45
- Lufkin E G, Wahner H W, O'Fallon W M, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9
- Henderson V W, Paganini-Hill A, Emanuel C K, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994; 51: 896–900
- Grodstein F, Stampfer M J, Colditz G A, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75
- Grady D, Rubin S M, Petitti D B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59
- Beresford S AA, Weiss N S, Voigt L F, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458–61
- Tavani A, La Vecchia C. The adverse effects of hormone replacement therapy. Drugs Aging 1999; 14: 347–57
- Ettinger B, Genant H, Steiger P, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 479–88
- Troy S M, Hicks D R, Parker V D, et al. Differences in pharmacokinetics and comparative bioavailability between Premarin® and Estratab® in healthy postmenopausal women. Curr Ther Res 1994; 55: 359–71
- Genant H K, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy Effects of bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med 1997; 157: 2609–15
- Kupperman H S, Blatt M HG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by menopausal amenorrheal indices. J Clin Endocrinol Metab 1953; 13: 688–703
- Greene J G. Constructing a standard climacteric scale. Maturitas 1998; 29: 25–31
- Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions and physical health. Psychol Health 1992; 7: 45–54
- Wiklund I, Berg G, Hammar M, et al. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 1992; 14: 225–36
- Notelovitz M, Varner R E, Rebar R W, et al. Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens. Menopause 1997; 4: 80–8
- Trabal J F, Lenihan J P, Jr., Melchione T E, et al. Low-dose unopposed estrogens: preliminary findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period. Menopause 1997; 4: 130–8
- Grodstein F, Stampfer M J, Manson J E, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–61
- Limouzin-Lamothe M A, Mairon N, Joyce C R, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994; 170: 618–24
- Derman R J, Dawood M Y, Stone S. Quality of life during sequential hormone replacement therapy - a placebo-controlled study. Int J Fertil Menopausal Stud 1995; 40: 73–8
- Zethraeus N, Johannesson M, Henriksson P, Strand R T. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 1997; 104: 1191–5
- Hilditch J R, Lewis J, Ross A H, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas 1996; 24: 177–84